5-Azacytidine was found to be bactericidal to Escherichia coli carrying plasmids specifying EcoRII restriction-modification systems, but not to the same strains lacking these plasmids. Of other base analogs tested, only 5(13-D-ribofuranosyl)isocytidine had similar, although weaker, effects. Plasmids that had lost the EcoRII restriction-modification system did not confer sensitivity to 5-azacytidine. Mutants defective in the restriction function remained sensitive to the toxic effects of the drug; however, a mutant defective in the modification function lost most of the sensitivity to 5-azacytidine. For the bactericidal effect to be seen, the cells had to be growing; cells in the stationary phase of growth were not killed by the drug. The drug inhibited the methylase enzyme, and an inhibitor of the enzyme could be detected in vitro in extracts of cells that had been treated with 5-azacytidine. This inhibitor was destroyed by DNase, and antibiotics such as coumermycin and nalidixic acid inhibited its formation. Coumermycin but not nalidixic acid antagonized the bactericidal effect of the drug; however, coumermycin was more effective in preventing the inhibition of the methylase by 5-azacytidine than was nalidixic acid.
5-Azacytidine inhibits several bacterial DNA (cytosine-5)methylases, but not the DNA (N6-adenine)methylase present in the same organism (9, 10) . For inhibition to occur in vivo, the cells must be growing; the enzyme is not inhibited when resting cells are treated with the drug. The inhibition could not be produced by treating cell extracts with 5-azacytidine; however, DNA (cytosine-5)methylases could be inhibited irreversibly, in vitro, if they were incubated with 5-azacytosine-containing DNA. For inhibition to occur, the DNA sequence that would otherwise be methylated had to be intact because prior digestion of 5-azacytosine-containing DNA with the complementary restriction enzyme destroyed the inhibitory activity of the DNA for the methylase (10) .
Modification of DNA protects that DNA from the complementary restriction enzyme (22) . If inhibition of the modification methylase should eventually lead to the presence of completely unmodified DNA in the cell, such DNA would be degraded by the restriction endonuclease. Thus, cells containing cytosine-dependent restriction-modification systems should not form viable progeny when grown in the presence of 5-azacytidine.
5-Azacytidine is also an inhibitor of bacterial cell growth. This inhibition is believed to be due to incorporation of the drug and its deaminated product, 5-azauridine, into mRNA, with resultant inhibition of protein synthesis; however, DNA synthesis is only slightly affected (7, 21) .
The inhibition of growth caused by the drug can be readily reversed by removing it from the growth medium (4) .
I have now tested cells containing the EcoRII restriction-modification system for the ability to resume growth after being treated with 5-azacytidine for a brief period of time. These cells lose viability after removal of the drug. However, the bactericidal effect is due not to the presence of the restriction enzyme, but is a function of the methylase.
MATERIALS AND METHODS
5-Azacytidine, 5-fluorouracil, 5-azauracil, 5-azacytosine, and 6-azauridine were obtained from Sigma Chemical Co., St. Louis, Mo. system. The modification enzyme methylates the second cytosine in the sequence CCAGG protecting the DNA from hydrolysis by the restriction endonuclease (22) . Escherichia coli strain K-12 and its derivatives contain an enzyme specified by the mec gene product that methylates the identical cytosine (12, 13). Minimal A medium (19) was supplemented with 1% Casamino Acids. The medium was supplemented with thiamine (1 pg/ml) when required. Bacteria were plated on yeast extract tryptone medium containing 1.5% agar (19) .
The bacteria were cultivated in 10 ml of medium in 250-ml side-arm flasks (Bellco) in a reciprocating shaker at 37°C. Growth was recorded by turbidity readings in a Klett-Summerson colorimeter with a no. 54 filter.
When the cells reached 50 Klett units (108 cells/ml), equal portions were removed and placed in 16 x 100-mm tubes containing drug as indicated. The tubes were shaken at 37°C. Samples were removed at the indicated times and plated for viable cells.
Phage restriction and modification and efficiency of plating (EOP) were determined as described by Wood (25) . Plasmid transfer was performed as described by Bannister and Glover (2), and transfection was performed as described by Cohen and Chang (5) .
Enzyme preparation. Cells were grown in 25 ml of medium as described above, harvested by centrifugation, and washed once with buffer containing 0.01 M Tris-hydrochloride and 1 mM EDTA, pH 8. The cells were suspended in 1 ml of buffer containing 0.01 M potassium phosphate, pH 7, 1 mM EDTA, 7 mM 2-mercaptoethanol, 1 mM sodium azide, 0.4 M sodium chloride, and 25 ,ug of phenylmethylsulfonyl fluoride per ml and sonicated with two 30-s bursts in a Branson sonicator. The extract was centrifuged at 40,000 rpm in a Beckman 40 rotor for 60 min, and the supernatant was used as a source of enzyme or inhibitor.
Enzymes assays. DNA methylase activity measured the incorporation of radioactivity from S-adenosyl-[methyl-14C]methionine into alkali-stable, acid-precipitable material resistant to deproteinization as described by Kalousek and Morris (15) , except that treatment with sodium hydroxide was performed only once and the DNA was dissolved in 0.3 ml of 0.2 N ammonia, and the radioactivity was determined in a liquid scintillation counter. The reaction mixture contained, per ml: 40 ,umol of Tris-hydrochloride, pH 8; In some experiments the methylated bases were identified as previously described (9) . Less than 2% of the radioactivity incorporated into 5-methylcytosine was incorporated into N6-methyladenine with extracts of E. coli B, or K-12 derivatives, containing the plasmid-specified EcoRII methylase. Ten percent of the radioactivity was incorporated into N6-methyladenine with extracts of mec+ K-12 strains not containing these plasmids.
Enzyme inhibition studies were performed by incubating partially purified enzyme prepared from E. coli B(R15) (10) with 0.01 ml of cell extract for 5 min at 37°C in a 0.2-ml reaction mixture before the addition of E. coli B DNA and S-adenosylmethionine as described above. Protein was determined by the method of Lowry et al. (16) .
RESULTS
Effect of 5-azacytidine on ceil growth. 5-Azacytidine at 20 pLg/ml inhibited growth of E. coli B, but this inhibition was completely reversible (Fig. 1) . When an EcoRII restriction-modification system was placed in these cells, their response to 5-azacytidine changed. Recovery was much slower than with cells rnot containing the plasmid, and after 1 h growth ceased. Greater than 98% of the cells were killed within 15 min (Fig. 2) of addition of 5-azacytidine (20 ,ug/ml) to the growing cells. E. coli B was resistant to this effect of 5-azacytidine; even at 1 mg of azacytidine per ml, no bactericidal effect was seen (data not shown).
Effect of base analogs on the growth ofE. coli B Table   3 ).
Deamination of 5-azacytidine to 5-azauridine was not required for cell death, as has been suggested for its inhibition of cell growth (8) , since it was bactericidal to strain S(441(N3), which lacks the enzyme cytidine deaminase. The cells had to be growing for the bactericidal effect of the drug to be observed; stationaryphase cells were not killed by the drug.
Effect of azacytidine on EcoRII restrictionmodification mutants. E. coli B containing the mutant plasmid deficient in restriction responded to azacytidine just as did strains containing the wild-type plasmid (Table 3 ). This was also true of three restriction mutants of plasmid R15 isolated by us (data not shown).
A modification mutant, supplied by S. man (23) , was found to be relatively resistant to the bactericidal effect of 5-azacytidine in E. coli B, although cells containing the plasmid were more sensitive to the drug than were cells lacking it. This methylase mutant is an ambersuppressible mutant, and the effect of 5-azacytidine on cells containing this mutation was also tested in F1100 mec, a suppressing strain. F1100 mec [N3 Res-Mod(Am) (RII)] was more resistant to 5-azacytidine than were strains containing either the wild-type plasmid or an N3 ResMod' (RII) plasmid, but more sensitive than F1100 mec itself. E. coli K-12 contains a cytosine methylase which has the same specificity as the EcoRII methylase (12, 13) , but K-12 strains were resistant to the bactericidal effect of 5-azacytidine.
Methylase levels in E. coli strains. As shown by May and Hattman (18) and confirmed here, E. coli K-12 had very low methylase levels compared with strains carrying plasmids that specify EcoRII restriction-modification enzymes, and E. coli B containing the Res-Mod(Am) (RII) plasmid had barely detectable levels of methylase-less than 1% of the activity in strains carrying the wild-type plasmid. F1100 mec Su' carrying this plasmid had methylase levels that were one-third the level in strains carrying Res' Mod' (RII) or Res-Mod' (RII) plasmids (Table   3) . These strains were also tested for the ability to modify phage by measuring the EOP on strains carrying the EcoRII restriction-modification system ( T1-F1100(N3). With phage X, however, the efficiency of plating of XAF1100(N3) and XAF1100 mec[N3 Res-Mod(Am) (RII)] was approximately the same. The N3 system appeared to be more efficient in modifying X than Ti (Table 4) . The failure of F1100 mec to completely suppress the amber mutation could therefore be detected with Ti phage but not with X.
Effect of inhibition of DNA synthesis on the killing effect of 5-azacytidine. Presumably, 5- 5- 0.15 azacytidine a E. coli B(R15) was grown to 50 to 55 Klett units of turbidity; portions were treated with 50 1Lg of antibiotic per ml, except for novobiocin, which was used at 500 ,ug/ml, for 10 min; 20 ,ug of azacytidine per ml was then added, and colony-forming units (CFU) or enzyme concentration was determined 20 min later.
b Standard deviation. c Number of determinations.
azacytidine kills E. coli B(R15) because it inhibits the DNA (cytosine-5)methylase present in these cells. Since in vitro this enzyme is inhibited by 5-azacytosine-containing DNA, we tested several inhibitors of DNA synthesis for their ability to inhibit the killing effect of 5-azacytidine. Coumermycin partially blocked the killing effect of 5-azacytidine; more cells survived the combined treatment than survived treatment with 5-azacytidine alone, even though coumermycin killed 70% of the cells. Novobiocin also protected the cells from the bactericidal effect of 5-azacytidine, but it was not as effective as coumermycin. Pretreatment with nalidixic acid did not protect against 5-azacytidine (Table 5) . Incorporation of thymidine was completely inhibited by the dose of nalidixic acid used. Chloramphenicol did not protect cells against the effects of 5-azacytidine. I determined whether there was any correlation between the ability of these drugs to inhibit the killing effect of azacytidine and their ability to decrease the inhibition of the DNA methylase caused by 5-azacytidine. Both coumermycin and nalidixic acid decreased the enzyme inhibition caused by 5-azacytidine, but treatment with coumermycin afforded better protection than did treatment with nalidixic acid (Table 5) .
Extracts of cells treated with azacytidine alone, or chloramphenicol plus azacytidine, contained an inhibitor of the enzyme (Table 6 ). This inhibitor could be completely destroyed by incubating the extract with pancreatic DNase. No such inhibitor could be detected in cells that had been pretreated with either nalidixic acid or coumermycin, although the methylase activity was lower in these extracts than in extracts of control cells (Table 5 ). The synthesis of the inhibitor in cells exposed to 5-azacytidine was independent of the presence of plasmids specifying EcoRII systems because extracts prepared from 5-azacytidine-treated E. coli B cells also inhibited the methylase ( Table 6) .
Addition of crude extract to purified enzyme always caused an increase in the amount of product formed, even when the crude extract came from E. coli B, which has no DNA cytosine methylase of its own. This stimulatory effect was also seen with the extracts obtained from cells treated with 5-azacytidine and either coumermycin or nalidixic acid.
DISCUSSION
Treatment with 5-azacytidine was lethal to cells containing plasmids specifying EcoRII restriction-modification systems but not cells lack- (Fig.  2) . Furthermore, the cells must be growing for the bactericidal effect to occur; cells in stationary phase are resistant to the drug (Table 3) . These findings are consistent with the inhibitor not being 5-azacytidine itself, but either 5-azacytosine in DNA or a metabolite of the drug.
The lethal effect is due to the presence of the EcoRII restriction-modification system in the cell, since plasmids not containing this system, or that have lost it due to deletion, do not confer sensitivity to the drug. It does not occur in cells having restriction-modification systems dependent on adenine methylation, since E. coli strains K-12 and B both contain such systems (22) .
Sensitivity to the drug is not a function of the presence of the restriction enzyme, since mutants lacking this enzyme are still sensitive to the drug (Table 3) . Sensitivity is a nonlinear correlate of the EcoRII methylase activity. A mutant deficient in this enzyme is much less sensitive to the drug than cells containing the enzyme (Table  3) . The mutation is an amber mutation, and a strain carrying a suppressor, E. coli F1100 mec, which expresses 30% of the wild-type enzyme (Table 3) , is relatively insensitive to the effects of 5-azacytidine. Furthermore, K-12 strains, which contain 10 to 20% of the methylase activity present in plasmid-containing strains, are resistant to the bactericidal effects of this drug.
Since the methylase is not necessary for cell viability, it is surprising that inhibition of this enzyme should result in cell death. One plausible explanation, consistent with my earlier findings on the mechanism of inhibition of the methylase, is that the enzyme reacts irreversibly with azacytosine-containing DNA, inhibiting further DNA and RNA synthesis. Drugs that inhibit DNA synthesis were tested to determine whether they would prevent the lethal effect of 5-azacytidine. Coumermycin inhibited the lethal effect of 5-azacytidine, novobiocin partially blocked the killing effect, and nalidixic acid had no detectable effect at a concentration that completely inhibited thymidine incorporation. Consistent with these results is that coumermycin prevented the inhibition of the methylase by azacytidine to a greater extent than did nalidixic acid (Table 5 ). Since nalidixic acid did not prevent the bactericidal effect of 5-azacytidine, we cannot at present be certain that the proposed mechanism is correct.
The current experiments indicate that there is some function of the methylase, in cells carrying plasmids that specify the EcoRII enzyme, that sensitizes these cells to 5-azacytidine. We shall have to isolate additional methylase mutants to ascertain the relationship between the function of the methylase and the bactericidal effect of the drug. These experiments do, however, indicate that a drug that inhibits a superfluous enzyme system, which does not metabolize that drug to an active metabolite, can cause cell death.
